FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951897223> ?p ?o ?g. }

• W2951897223 endingPage "1526" @default.
• W2951897223 startingPage "1517" @default.
• W2951897223 abstract "Purpose Neodymium:yttrium–aluminum–garnet (Nd:YAG) laser treatment is performed on vitreous floaters, but studies of structural and functional effects with objective outcome measures are lacking. This study evaluated Nd:YAG laser effects by comparing participants with vitreous floaters who previously underwent laser treatment with untreated control participants and healthy persons without vitreous floaters using quantitative ultrasonography to evaluate vitreous structure and by measuring visual acuity and contrast sensitivity function to assess vision. Design Retrospective, comparative study. Participants One eye was enrolled for each of 132 participants: 35 control participants without vitreous floaters, 59 participants with untreated vitreous floaters, and 38 participants with vitreous floaters previously Nd:YAG-treated. Of these, 25 were dissatisfied and sought vitrectomy; 13 were satisfied with observation. Methods The 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-39) to assess participant visual well-being, quantitative ultrasonography (QUS) to measure vitreous echodensity, and best-corrected visual acuity (BCVA) and contrast sensitivity function (CSF) to evaluate vision. Main Outcome Measures Results of NEI-VFQ-39, QUS, BCVA, and CSF. Results Compared with control participants without vitreous floaters, participants with untreated vitreous floaters showed worse NEI-VFQ-39 results, 57% greater vitreous echodensity, and significant (130%) CSF degradation (P < 0.001 for each). Compared with untreated eyes with vitreous floaters, Nd:YAG-treated eyes had 23% less vitreous echodensity (P < 0.001), but no differences in NEI-VFQ-39 (P = 0.51), BCVA (P = 0.42), and CSF (P = 0.17) results. Of 38 participants with vitreous floaters who previously were treated with Nd:YAG, 25 were dissatisfied and seeking vitrectomy, whereas 13 were satisfied with observation. Participants seeking vitrectomy showed 24% greater vitreous echodensity (P = 0.018) and 52% worse CSF (P = 0.006). Multivariate linear regression models confirmed these findings. Conclusions As a group, participants previously treated with Nd:YAG laser for bothersome vitreous floaters showed less dense vitreous, but similar visual function as untreated control participants with vitreous floaters. Because some treated eyes showed less dense vitreous and better visual function than those of untreated control participants, a prospective randomized study of Nd:YAG laser treatment of vitreous is warranted, using uniform laser treatment parameters and objective quantitative outcome measures. Neodymium:yttrium–aluminum–garnet (Nd:YAG) laser treatment is performed on vitreous floaters, but studies of structural and functional effects with objective outcome measures are lacking. This study evaluated Nd:YAG laser effects by comparing participants with vitreous floaters who previously underwent laser treatment with untreated control participants and healthy persons without vitreous floaters using quantitative ultrasonography to evaluate vitreous structure and by measuring visual acuity and contrast sensitivity function to assess vision. Retrospective, comparative study. One eye was enrolled for each of 132 participants: 35 control participants without vitreous floaters, 59 participants with untreated vitreous floaters, and 38 participants with vitreous floaters previously Nd:YAG-treated. Of these, 25 were dissatisfied and sought vitrectomy; 13 were satisfied with observation. The 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-39) to assess participant visual well-being, quantitative ultrasonography (QUS) to measure vitreous echodensity, and best-corrected visual acuity (BCVA) and contrast sensitivity function (CSF) to evaluate vision. Results of NEI-VFQ-39, QUS, BCVA, and CSF. Compared with control participants without vitreous floaters, participants with untreated vitreous floaters showed worse NEI-VFQ-39 results, 57% greater vitreous echodensity, and significant (130%) CSF degradation (P < 0.001 for each). Compared with untreated eyes with vitreous floaters, Nd:YAG-treated eyes had 23% less vitreous echodensity (P < 0.001), but no differences in NEI-VFQ-39 (P = 0.51), BCVA (P = 0.42), and CSF (P = 0.17) results. Of 38 participants with vitreous floaters who previously were treated with Nd:YAG, 25 were dissatisfied and seeking vitrectomy, whereas 13 were satisfied with observation. Participants seeking vitrectomy showed 24% greater vitreous echodensity (P = 0.018) and 52% worse CSF (P = 0.006). Multivariate linear regression models confirmed these findings. As a group, participants previously treated with Nd:YAG laser for bothersome vitreous floaters showed less dense vitreous, but similar visual function as untreated control participants with vitreous floaters. Because some treated eyes showed less dense vitreous and better visual function than those of untreated control participants, a prospective randomized study of Nd:YAG laser treatment of vitreous is warranted, using uniform laser treatment parameters and objective quantitative outcome measures." @default.
• W2951897223 created "2019-06-27" @default.
• W2951897223 creator A5013092199 @default.
• W2951897223 creator A5034544046 @default.
• W2951897223 creator A5056101155 @default.
• W2951897223 creator A5063488128 @default.
• W2951897223 creator A5065452265 @default.
• W2951897223 creator A5076167293 @default.
• W2951897223 creator A5077691081 @default.
• W2951897223 creator A5085652152 @default.
• W2951897223 date "2019-11-01" @default.
• W2951897223 modified "2023-10-03" @default.
• W2951897223 title "Assessment of Vitreous Structure and Visual Function after Neodymium:Yttrium–Aluminum–Garnet Laser Vitreolysis" @default.
• W2951897223 cites W141126648 @default.
• W2951897223 cites W1515340643 @default.
• W2951897223 cites W173386824 @default.
• W2951897223 cites W1967599611 @default.
• W2951897223 cites W1972783723 @default.
• W2951897223 cites W1973622128 @default.
• W2951897223 cites W1982602058 @default.
• W2951897223 cites W1983115839 @default.
• W2951897223 cites W2001065429 @default.
• W2951897223 cites W2013097262 @default.
• W2951897223 cites W2019972759 @default.
• W2951897223 cites W2026521319 @default.
• W2951897223 cites W2027931506 @default.
• W2951897223 cites W2048790927 @default.
• W2951897223 cites W2057208277 @default.
• W2951897223 cites W2064364291 @default.
• W2951897223 cites W2066010983 @default.
• W2951897223 cites W2071486674 @default.
• W2951897223 cites W2073319632 @default.
• W2951897223 cites W2078470222 @default.
• W2951897223 cites W2078785673 @default.
• W2951897223 cites W2088506850 @default.
• W2951897223 cites W2090790155 @default.
• W2951897223 cites W2109507723 @default.
• W2951897223 cites W2113491252 @default.
• W2951897223 cites W2135521941 @default.
• W2951897223 cites W2196444154 @default.
• W2951897223 cites W2258092834 @default.
• W2951897223 cites W2288695907 @default.
• W2951897223 cites W2317993629 @default.
• W2951897223 cites W2327275898 @default.
• W2951897223 cites W2343509028 @default.
• W2951897223 cites W2464867386 @default.
• W2951897223 cites W2515753094 @default.
• W2951897223 cites W2520957924 @default.
• W2951897223 cites W2522866923 @default.
• W2951897223 cites W2565124205 @default.
• W2951897223 cites W2565182282 @default.
• W2951897223 cites W2616963898 @default.
• W2951897223 cites W2620712172 @default.
• W2951897223 cites W2739322609 @default.
• W2951897223 cites W2739408580 @default.
• W2951897223 cites W2740455954 @default.
• W2951897223 cites W2791026827 @default.
• W2951897223 cites W2791157006 @default.
• W2951897223 cites W2791709633 @default.
• W2951897223 cites W2792379031 @default.
• W2951897223 cites W2794394118 @default.
• W2951897223 cites W2802532377 @default.
• W2951897223 doi "https://doi.org/10.1016/j.ophtha.2019.06.021" @default.
• W2951897223 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6810832" @default.
• W2951897223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31471088" @default.
• W2951897223 hasPublicationYear "2019" @default.
• W2951897223 type Work @default.
• W2951897223 sameAs 2951897223 @default.
• W2951897223 citedByCount "26" @default.
• W2951897223 countsByYear W29518972232019 @default.
• W2951897223 countsByYear W29518972232020 @default.
• W2951897223 countsByYear W29518972232021 @default.
• W2951897223 countsByYear W29518972232022 @default.
• W2951897223 countsByYear W29518972232023 @default.
• W2951897223 crossrefType "journal-article" @default.
• W2951897223 hasAuthorship W2951897223A5013092199 @default.
• W2951897223 hasAuthorship W2951897223A5034544046 @default.
• W2951897223 hasAuthorship W2951897223A5056101155 @default.
• W2951897223 hasAuthorship W2951897223A5063488128 @default.
• W2951897223 hasAuthorship W2951897223A5065452265 @default.
• W2951897223 hasAuthorship W2951897223A5076167293 @default.
• W2951897223 hasAuthorship W2951897223A5077691081 @default.
• W2951897223 hasAuthorship W2951897223A5085652152 @default.
• W2951897223 hasBestOaLocation W29518972232 @default.
• W2951897223 hasConcept C118487528 @default.
• W2951897223 hasConcept C119767625 @default.
• W2951897223 hasConcept C2777104736 @default.
• W2951897223 hasConcept C2778257484 @default.
• W2951897223 hasConcept C2779676219 @default.
• W2951897223 hasConcept C2781242345 @default.
• W2951897223 hasConcept C71924100 @default.
• W2951897223 hasConceptScore W2951897223C118487528 @default.
• W2951897223 hasConceptScore W2951897223C119767625 @default.
• W2951897223 hasConceptScore W2951897223C2777104736 @default.
• W2951897223 hasConceptScore W2951897223C2778257484 @default.
• W2951897223 hasConceptScore W2951897223C2779676219 @default.
• W2951897223 hasConceptScore W2951897223C2781242345 @default.
• W2951897223 hasConceptScore W2951897223C71924100 @default.

• next